Notch信号通路在乳腺癌干细胞中的研究进展

郭瑢; 张瑾

doi:10.3969/j.issn.1000-8179.20140812

Notch信号通路在乳腺癌干细胞中的研究进展

doi: 10.3969/j.issn.1000-8179.20140812

郭瑢,
张瑾^,

天津医科大学肿瘤医院乳腺肿瘤三科，国家肿瘤临床医学研究中心，中国天津乳腺癌防治研究中心，天津市肿瘤防治重点实验室，乳腺癌防治教育部重点实验室（天津市 300060）

基金项目:

天津市科技项目 12ZCDZSY15700

详细信息

作者简介:
郭瑢在读硕士研究生。研究方向为乳腺肿瘤外科。E-mail：ynkmgr@126.com

通讯作者:
张瑾 E-mail:zhangjin@tjmuch.com

计量
- 文章访问数: 25
- HTML全文浏览量: 26
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-15
- 修回日期: 2014-06-29
- 刊出日期: 2020-12-31

Research progress in notch signaling pathway in breast cancer stem cells

GUO Rong,
ZHANG Jin^,

The Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment, and Research Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

Funds:

Municipal Key Special Project of Tianjin 12ZCDZSY15700

More Information

Corresponding author: Jin ZHANG; E-mail:zhangjin@tjmuch.com

摘要

摘要: 乳腺癌干细胞是一群具有自我更新及多向分化潜能的细胞，在乳腺癌的发生、发展以及转移、复发中起着极其重要的作用。正常情况下，乳腺干细胞的分化、更新能力受相关信号转导通路的严格调控，当这些信号通路发生异常干细胞将会异常分化，形成乳腺癌干细胞，并无限增殖形成肿瘤。随着人们对乳腺癌干细胞的深入研究，Notch信号通路与其他信号通路的相互作用对乳腺癌干细胞的调控逐渐被人们所重视。本文为进一步了解Notch信号通路在乳腺癌的发生、发展以及靶向治疗中的重要意义，结合乳腺癌干细胞信号通路的最新研究进展进行综述。
- Notch /
- 信号通路 /
- 乳腺癌 /
- 乳腺癌干细胞 /
- 靶向治疗
Abstract: Breast cancer stem cells (BCSC) are group of cells exhibiting self-renewal and multi-directional differentiation potentials. These cells have an important role in the occurrence, development, metastasis, and recurrence of breast cancer. In normal circumstances, the ability of mammary stem cells to differentiate and undergo self-renewal is governed by related signaling pathways. After this mechanism is destroyed, breast stem cells undergo abnormal differentiation, forming breast cancer stem cells that unlimitedly proliferate to develop into breast cancer. As research on BCSC increasingly deepens, regulation of BCSC by notch signaling and its crosstalk with several signaling pathways have drawn a great deal of attention in this field. This paper reports the signaling pathways of breast cancer stem cells and latest studies on this field to better understand the essential role of notch signaling pathway in the occurrence and development of breast cancer and corresponding clinical targeted therapy.
- Notch /
- signaling pathway /
- breast cancer /
- breast cancer stem cells /
- targeting therapy

HTML全文

参考文献(22)

[1] Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development[J]. Science, 1999, 284(5415):770-776. doi: 10.1126/science.284.5415.770
[2]	Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges[J]. Pharmacol Ther, 2014, 141(2):140-149. http://cn.bing.com/academic/profile?id=2894f62bde070b2c15ac897713b8c733&encoded=0&v=paper_preview&mkt=zh-cn
[3]	Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer[J]. Biochim Biophys Acta, 2011, 1815(2):197-213. http://cn.bing.com/academic/profile?id=694684d10d7c961844e938c84a82adff&encoded=0&v=paper_preview&mkt=zh-cn
[4]	Peng GL, Tian Y, Lu C, et al. Effects of notch-1 down-regulation on malignant behaviors of breast cancer stem cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2):195-200. doi: 10.1007/s11596-014-1258-4
[5]	Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor[J]. Cancer Res, 2010, 70(2):709-718. doi: 10.1158/0008-5472.CAN-09-1681
[6]	Fu YP, Edvardsen H, Kaushiva A, et al. Notch2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations[J]. Mol Cancer, 2010, 9:113. http://cn.bing.com/academic/profile?id=ce48ab2358114337236be54ce2eb361f&encoded=0&v=paper_preview&mkt=zh-cn
[7]	Lafkas D, Rodilla V, Huyghe M, et al. Notch3 marks clonogenic mammary luminal progenitor cells in vivo[J]. J Cell Biol, 2013, 203 (1):47-56. doi: 10.1083/jcb.201307046
[8]	Ling H, Sylvestre JR, Jolicoeur P. Cyclin D1-dependent induction of luminal inflammatory breast tumors by activated notch3[J]. Cancer Res, 2013, 73(19):5963-5973. doi: 10.1158/0008-5472.CAN-13-0409
[9]	Brechbiel J, Miller-Moslin K, Adjei AA. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer[J]. Cancer Treat Rev, 2014, 40(6)750-759. doi: 10.1016/j.ctrv.2014.02.003
[10]	Schreck KC, Taylor P, Marchionni L, et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance[J]. Clin Cancer Res, 2010, 16(24): 6060-6070. doi: 10.1158/1078-0432.CCR-10-1624
[11]	Ayyanan A, Civenni G, Ciarloni L, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism[J]. Proc Natl Acad Sci U S A, 2006, 103(10):3799-3804. doi: 10.1073/pnas.0600065103
[12]	Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think[J]. J Exp Med, 2011, 208(10):1931-1935. doi: 10.1084/jem.20111855
[13]	Meurette O, Stylianou S, Rock R, et al. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells[J]. Cancer Res, 2009, 69(12):5015-5022. doi: 10.1158/0008-5472.CAN-08-3478
[14]	Efferson CL, Winkelmann CT, Ware C, et al. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/ mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model[J]. Cancer Res, 2010, 70(6): 2476-2484. doi: 10.1158/0008-5472.CAN-09-3114
[15]	Zhu H, Bhaijee F, Ishaq N, et al. Correlation of Notch1, pAKT and nuclear NF-kappaB expression in triple negative breast cancer[J]. Am J Cancer Res, 2013, 3(2):230-239. https://www.researchgate.net/profile/Lucio_Miele/publication/236207914_Correlation_of_Notch1_pAKT_and_nuclear_NF-kB_expression_in_triple_negative_breast_cancer/links/00b7d5295074dd8e52000000/Correlation-of-Notch1-pAKT-and-nuclear-NF-kB-expression-in-triple-negative-breast-cancer.pdf
[16]	Zhang CC, Pavlicek A, Zhang Q, et al. Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models[J]. Clin Cancer Res, 2012, 18(18):5008-5019. doi: 10.1158/1078-0432.CCR-12-1379
[17]	Zhang CC, Yan Z, Zong Q, et al. Synergistic effect of the gamma-secretase inhibitor PF-03084014 and docetaxel in breast cancer models[J]. Stem Cells Transl Med, 2013, 2(3):233-242. https://www.ncbi.nlm.nih.gov/pubmed/23408105
[18]	Krop I, Demuth T, Guthrie T, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors[J]. J Clin Oncol, 2012, 30(19):2307-2313. doi: 10.1200/JCO.2011.39.1540
[19]	Schott AF, Landis MD, Dontu G, et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors[J]. Clin Cancer Res, 2013, 19(6):1512-1524. doi: 10.1158/1078-0432.CCR-11-3326
[20]	Speiser J, Foreman K, Drinka E, et al. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer[J]. Int J Surg Pathol, 2012, 20(2):139-145. http://cn.bing.com/academic/profile?id=d6dfafecf7ae49d2f76785431733a083&encoded=0&v=paper_preview&mkt=zh-cn
[21]	Azzam DJ, Zhao D, Sun J, et al. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in gamma-secretase inhibitor drug responses[J]. EMBO Mol Med, 2013, 5(10):1502-1522. doi: 10.1002/emmm.201302558
[22]	Hoey T, Yen WC, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency[J]. Cell Stem Cell, 2009, 5(2):168-177. http://cn.bing.com/academic/profile?id=aaeb54f7f981692379fcb93e64d34123&encoded=0&v=paper_preview&mkt=zh-cn